You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Rapid Response Vaccines for Botulinum Neurotoxins
SBC: Iterative Therapeutics Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most potent protein toxins known. Given their potent toxicity and their potential use in bio-warfare scenarios, BoNTs are included among the Category A select agents. The currentlyavailable pentavalent toxoid vaccine requires multiple boosters before being effective, and protects unequally against the different BoNT serotyp ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Coated Scaffolds for Intra-Operative Protein Incorporation and Controlled Release
SBC: TISSUE REGENERATION SYSTEMS, INC. Topic: NIAMSDESCRIPTION (provided by applicant): The purpose of the proposal is to develop medical device coatings that bind and release therapeutic proteins, particularly growth factors. Specifically, we propose to systematically optimize and control growth factor binding and release using protocols that can be translated to the operating room. Bone fracture repair and reconstruction of critical-sized defect ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
VerOFy: A New Tool to Improve Productivity and Reduce Costs for Stress Research
SBC: OASIS DIAGNOSTICS CORPORATION Topic: NCCAMDESCRIPTION (provided by applicant): This Phase 1 NIH SBIR proposal is for support of an interdisciplinary program involving the Oasis Diagnostics(R) Corporation, Madison Biodiagnostics, LLC, and the University of New Orleans who seek to collaboratively demonstrate an innovative saliva collection and analysis system (VerOFy(R)) for measurement of cortisol levels at the point of sampling for measur ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Multifunctional Peptides for (MRI) Imaging
SBC: CDG THERAPEUTICS, INC. Topic: NCIDESCRIPTION (provided by applicant): Our overall goal is to expand the role of CPPs in molecular imaging at the patient level using large animal models of human tumors and a peptide agent that inherently provides 1) preferential access to a wide variety ofhuman solid (and hematologic) tumor cells, 2) an increased intracellular concentration (2-12 fold) over histologically matched normal cells, and ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Reducing Complement Inhibition to Treat Leukemia and Lymphoma
SBC: Compliment Corporation Topic: NCIDESCRIPTION (provided by applicant): The funding of the application will yield safety and efficacy data on a new combination cancer therapy for leukemia and lymphomas. Monoclonal antibodies (mAbs) have emerged as a class of novel oncology therapeutics. Weare developing a molecule that can improve the therapeutic effects of mAbs by: 1) increasing the sensitivity of cancers to treatment 2) unmaskin ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Analgesics Targeting TRPA1 for Treatment of Chronic Pain
SBC: ALGOMEDIX, INC. Topic: NIDADESCRIPTION (provided by applicant): Title: Analgesics Targeting TRPA1 for Treatment of Chronic Pain Abstract An effective treatment for chronic pain that is devoid of both addictive potential and abuse liability is a major unmet need in medicine today. These limitations drive the need for novel treatment options based on new molecular mechanisms. Our goal is to identify and develop a novel, ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Optimal Prevention and Control of Periodontal Disease: The Periodontal Pocket Irr
SBC: C. PAXTON DESIGNS INC. Topic: NIDCRDESCRIPTION (provided by applicant): Periodontal disease is a chronic bacterial infection that affects the gums and bone that surrounds supported teeth. According to the NIH fact sheet an estimated 80 percent of American adults have some form of periodontal disease. Gingivitis, a milder form of gum disease, is caused by plaque bio-film, which surrounds the teeth at the base of the gum line, causin ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Vaccine for HIV/HPV-associated Oropharyngeal and Tonsillar Malignanci
SBC: Etubics Corporation Topic: NIDCRDESCRIPTION (provided by applicant): The objective of this project is to develop a therapeutic strategy for H V-associated malignancy based on the role of HPV in the pathogenesis. HPV related cancers express the E6/E7 oncoproteins of HPV that are ideal targets for immune inducing vaccines. We will develop a vaccine based upon a novel adenovirus serotype-S vector (Ads) platform with unique and addi ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
Advanced Hypoglycemia Prevention Capabilities in Fuzzy Logic Artificial Pancreas
SBC: DOSE SAFETY INC Topic: NIDDKDESCRIPTION (provided by applicant): The ultimate technical objective of this research is the development of an Artificial Pancreas (AP) controller that improves metabolic control and decreases glycemic excursions by robustly preventing hypoglycemic episodes. Proportional-integral-derivative control (PID) and model predictive control (MPC) have been widely considered to be promising candidate for ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health -
New drug Vida-5 for treating chronic kidney disease progression
SBC: Vidasym, Inc Topic: NIDDKDESCRIPTION (provided by applicant): Twenty-six million people in America have chronic kidney disease (CKD). Anemia, cardiovascular diseases, secondary hyperparathyroidism, renal osteodystrophy and other complications are common in CKD. Current treatmentsincluding ACE inhibitors for CKD patients mainly focus on managing symptoms and disease complications. Despite the various treatments available, ...
SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health